問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Hematology & Oncology

Division of Radiation Therapy

更新時間：2023-09-19

林敬業
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

37Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林敬業

List

79Cases

2017-09-25 - 2019-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2018-03-01 - 2020-05-31

Phase III

ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX

  • Condition/Disease

    Hemophilia A or B

  • Test Drug

    Fitusiran (ALN-AT3SC)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

張家堯
Taipei Medical University Hospital

Division of Pediatrics

2016-05-02 - 2021-05-12

Phase III

A Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults who require regular red blood cell transfusions due to beta (β)-thalassemia

  • Condition/Disease

    beta (β)-thalassemia

  • Test Drug

    Luspatercept (ACE-536)

Participate Sites
5Sites

Terminated4Sites

彭慶添
China Medical University Hospital-Taipei

未分科

2021-02-26 - 2023-10-24

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2019-01-22 - 2022-07-12

Phase III

A Randomized, Double-blind, Active-controlled, Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Test Drug

    ABP 959

Participate Sites
3Sites

Recruiting3Sites

2016-09-08 - 2019-10-31

Phase III

A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Vadastuximab Talirine

Participate Sites
4Sites

Terminated4Sites

蕭樑材
Taipei Veterans General Hospital

2014-01-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2018-07-01 - 2020-06-30

Phase III

A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

  • Condition/Disease

    Pancreatic Cancer

  • Test Drug

    EndoTAG-1

Participate Sites
12Sites

Terminated11Sites

白禮源
China Medical University Hospital-Taipei

未分科

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2019-10-01 - 2022-03-02

Phase III

A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

  • Condition/Disease

    Advanced or Metastatic Biliary Tract Cancer

  • Test Drug

    NUC-1031 for injection (Acelarin®)

Participate Sites
5Sites

Recruiting5Sites

2013-09-01 - 2016-06-21

Phase III

A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    Carfilzomib

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB